| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC60795 | Boscalid Featured | Boscalid is a broad-spectrum fungicide widely used in agriculture to protect crops from fungal diseases. Its bioactivity stems from its ability to inhibit fungal respiration by targeting succinate dehydrogenase (Complex II) in the mitochondrial electron transport chain. By binding to this enzyme, Boscalid blocks electron transfer, disrupting ATP synthesis and energy production in fungal cells, ultimately leading to their death. This mechanism makes Boscalid highly effective against a wide range of fungal pathogens, including Botrytis, Alternaria, Sclerotinia, and powdery mildew species. |
|
| DC67295 | MK16 Featured | MK-16 is a novel blood-brain-barrier (BBB)-crossing lipid nanoparticle (BLNP) platform designed for systemic mRNA delivery to the central nervous system. MK16 is synthesized by integrating MK-0752, a NOTCH inhibitor-derived small molecule, into an ionizable lipid structure through chemical engineering, eliminating the need for surface functionalization or BBB disruption. It demonstrates superior mRNA delivery efficiency, achieving over 8-fold higher luminescence intensity in the brain compared to standard MC3 LNPs after intravenous administration. MK16 effectively crosses the intact BBB via caveolae- and γ-secretase-mediated transcytosis pathways, a novel mechanism for nanomaterial transport. It delivers mRNA to multiple brain cell types, including neurons (38.6%), astrocytes (28.4%), brain capillary endothelial cells (18.3%), and microglia (12.7%), with dose-dependent efficacy. Despite using MK-0752 as a headgroup, RNA-seq analysis shows no significant NOTCH pathway activation or systemic toxicity, with immunogenic responses comparable to or milder than MC3 LNPs. MK 16 exhibits excellent biocompatibility, showing no hepatic/renal impairment or organ abnormalities even after repeated doses. Functionally, it enables region-specific delivery of Cre recombinase mRNA in transgenic mice and enhances drug-seeking behaviors via ΔFOSB expression in the nucleus accumbens, matching viral vector efficacy. Notably, MK16 delivers therapeutic Pten mRNA to orthotopic glioblastoma models, significantly reducing tumor burden and extending survival. Its clinical potential is further evidenced by successful ΔFOSB mRNA delivery to ex vivo human cortical tissues. The design allows systemic administration with minimal off-target effects, though some liver/spleen accumulation occurs, addressable through miRNA-targeted UTR modifications. MK16 represents a breakthrough in non-invasive, efficient, and safe brain-targeted mRNA therapeutics. |
|
